DBV Technologies Achieves Positive Results for Viaskin Peanut Patch in Children
DBV Technologies has announced promising preliminary results for the phase 3 VITESSE study, evaluating the Viaskin Peanut patch in children aged 4 to 7 years with peanut allergies.
Successful Primary Endpoint Achievement in Phase 3 Trial
DBV Technologies, listed on Euronext and Nasdaq, reported that the VITESSE phase 3 clinical trial met its primary endpoint for the Viaskin Peanut patch. After 12 months, 46.6% of the children treated with Viaskin Peanut showed a favorable response compared to 14.8% in the placebo group. The difference in response between the groups was 31.8% with a 95% confidence interval ranging from 24.5 to 39.0%, exceeding the predefined threshold of 15%.
Study Details and Safety Outcomes
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The study included 654 children, with 438 in the active group and 216 in the placebo group. Safety results were consistent with previous profiles, with mild to moderate adverse events primarily being skin reactions. The discontinuation rate due to these events was 3.2% in the active group and 0.5% in the placebo group.
Future Plans and Financial Position Strengthening
DBV Technologies plans to file for a Biologics License Application in the United States by the first half of 2026. The announcement of these results has triggered financing conditions, allowing the exercise of shares and warrants until January 15, 2026, thereby strengthening the company's financial position.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 1,6 millions de dollars
Quarterly revenue: 1,6 millions de dollars
Net income: -98 millions de dollars
Guidance from the release
DBV is a late-stage biopharmaceutical company currently in regulatory discussions with the FDA, with BLA submission anticipated in Q3 2026; the company reports cash funding into Q3 2027, indicating reliance on capital reserves and no current revenue generation.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
